Association of Vitamin D3 Level with Breast Cancer Risk and Prognosis in African-American and Hispanic Women

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2017 Oct 25

PMID 29064397

Citations 17

Authors

Yanyuan Wu

Marianna Sarkissyan

Sheilah Clayton

Rowan Chlebowski

Jaydutt V Vadgama

Affiliations

Soon will be listed here.

Abstract

: This study investigated the association of vitamin D3 levels with breast cancer risk and progression in African-Americans and Hispanics. : A total of 237 African-American (Cases = 119, Control = 118) and 423 Hispanic women (Cases = 124, Control = 299) were recruited in the study. Blood samples were collected at the time of breast cancer screening and prior to cancer treatment for 4 weeks on average for the cases. The serum 25-hydroxyvitamin D (25(OH)D3) was measured at a Quest-Diagnostics facility. : The results showed that 69.2% of African-Americans and 37.8% of Hispanics had 25(OH)D3 levels below 20 ng/mL. The 25(OH)D3 level below 20 ng/mL was significantly associated with breast cancer in both African-Americans (OR = 2.5, 95% CI = 1.3-4.8) and Hispanics (OR = 1.9, 95% CI = 1.1-3.0). However, the predicted probabilities of breast cancer in African-Americans were significantly higher than in Hispanics ( < 0.001). The 25(OH)D3 below 20 ng/mL was significantly associated with triple negative breast cancer (TNBC) in African-Americans (OR = 5.4, = 0.02, 95% CI = 1.4-15), but not in Hispanics in our cohort of participants. Levels of 25(OH)D3 below 26 ng/mL predicts a decrease in disease-free survival, but it was not an independent predictor. : Our data shows an association between 25(OH)D3 levels and the risk of breast cancer. Further studies on the relationship between 25(OH)D3 level and breast cancer risk are warranted.

Citing Articles

Anticancer and anti-metastasis activity of 1,25 dihydroxycholecalciferols and genistein in MCF-7 and MDA-MB-231 breast cancer cell lines.

Alatawi F, Faridi U Heliyon. 2023; 9(11):e21975.

PMID: 38034665 PMC: 10682641. DOI: 10.1016/j.heliyon.2023.e21975.

Emerging perspectives: unraveling the anticancer potential of vitamin D.

Wakle K, Mokale S, Sakle N Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(5):2877-2933.

PMID: 37994947 DOI: 10.1007/s00210-023-02819-5.

The Association between Vitamin D Deficiency and Fibrocystic Breast Disorder.

Shabanian S, Rozbeh A, Mohammadi B, Ahmadi A, Arjmand M Curr Mol Med. 2023; 24(7):899-905.

PMID: 37357512 DOI: 10.2174/1566524023666230623155659.

Postdiagnosis dietary factors, supplement use and breast cancer prognosis: Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis.

Becerra-Tomas N, Balducci K, Abar L, Aune D, Cariolou M, Greenwood D Int J Cancer. 2022; 152(4):616-634.

PMID: 36279902 PMC: 10092903. DOI: 10.1002/ijc.34321.

Association between serum Vitamin D levels and prognostic factors in nonmetastatic breast cancer patients.

Shahrzad M, Gharehgozlou R, Fadaei S, Hajian P, Mirzaei H J Res Med Sci. 2022; 27:56.

PMID: 36092485 PMC: 9450253. DOI: 10.4103/jrms.jrms_951_21.

References

Jensen S, Madsen M, Lukas J, Binderup L, Bartek J . Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol. 2001; 15(8):1370-80. DOI: 10.1210/mend.15.8.0673. View

Vrieling A, Seibold P, Johnson T, Heinz J, Obi N, Kaaks R . Circulating 25-hydroxyvitamin D and postmenopausal breast cancer survival: Influence of tumor characteristics and lifestyle factors?. Int J Cancer. 2013; 134(12):2972-83. DOI: 10.1002/ijc.28628. View

Forrest K, Stuhldreher W . Prevalence and correlates of vitamin D deficiency in US adults. Nutr Res. 2011; 31(1):48-54. DOI: 10.1016/j.nutres.2010.12.001. View

Mohr S, Gorham E, Alcaraz J, Kane C, Macera C, Parsons J . Serum 25-hydroxyvitamin D and prevention of breast cancer: pooled analysis. Anticancer Res. 2011; 31(9):2939-48. View

Yao S, Zirpoli G, Bovbjerg D, Jandorf L, Hong C, Zhao H . Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study. Breast Cancer Res. 2012; 14(2):R58. PMC: 3446393. DOI: 10.1186/bcr3162. View

Kristal A, Shattuck A, Patterson R . Differences in fat-related dietary patterns between black, Hispanic and White women: results from the Women's Health Trial Feasibility Study in Minority Populations. Public Health Nutr. 1999; 2(3):253-62. DOI: 10.1017/s1368980099000348. View

McCullough M, Stevens V, Patel R, Jacobs E, Bain E, Horst R . Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res. 2009; 11(4):R64. PMC: 2750126. DOI: 10.1186/bcr2356. View

Ginde A, Liu M, Camargo Jr C . Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med. 2009; 169(6):626-32. PMC: 3447083. DOI: 10.1001/archinternmed.2008.604. View

Goodwin P, Ennis M, Pritchard K, Koo J, Hood N . Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol. 2009; 27(23):3757-63. DOI: 10.1200/JCO.2008.20.0725. View

10.

Chlebowski R, Johnson K, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T . Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 2008; 100(22):1581-91. PMC: 2673920. DOI: 10.1093/jnci/djn360. View

11.

Park S, Lee D, Jeon J, Ryu J, Kim S, Kim J . Serum 25-hydroxyvitamin D deficiency and increased risk of breast cancer among Korean women: a case-control study. Breast Cancer Res Treat. 2015; 152(1):147-154. DOI: 10.1007/s10549-015-3433-0. View

12.

Yao S, Sucheston L, Millen A, Johnson C, Trump D, Nesline M . Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study. PLoS One. 2011; 6(2):e17251. PMC: 3046139. DOI: 10.1371/journal.pone.0017251. View

13.

Kim Y, Franke A, Shvetsov Y, Wilkens L, Cooney R, Lurie G . Plasma 25-hydroxyvitamin D3 is associated with decreased risk of postmenopausal breast cancer in whites: a nested case-control study in the multiethnic cohort study. BMC Cancer. 2014; 14:29. PMC: 3897897. DOI: 10.1186/1471-2407-14-29. View

14.

Palmer J, Gerlovin H, Bethea T, Bertrand K, Holick M, Ruiz-Narvaez E . Predicted 25-hydroxyvitamin D in relation to incidence of breast cancer in a large cohort of African American women. Breast Cancer Res. 2016; 18(1):86. PMC: 4983060. DOI: 10.1186/s13058-016-0745-x. View

15.

Yao S, Kwan M, Ergas I, Roh J, Cheng T, Hong C . Association of Serum Level of Vitamin D at Diagnosis With Breast Cancer Survival: A Case-Cohort Analysis in the Pathways Study. JAMA Oncol. 2016; 3(3):351-357. PMC: 5473032. DOI: 10.1001/jamaoncol.2016.4188. View

16.

Crowe F, Steur M, Allen N, Appleby P, Travis R, Key T . Plasma concentrations of 25-hydroxyvitamin D in meat eaters, fish eaters, vegetarians and vegans: results from the EPIC-Oxford study. Public Health Nutr. 2010; 14(2):340-6. DOI: 10.1017/S1368980010002454. View

17.

Yetley E . Assessing the vitamin D status of the US population. Am J Clin Nutr. 2008; 88(2):558S-564S. DOI: 10.1093/ajcn/88.2.558S. View

18.

Kim Y, Je Y . Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. Br J Cancer. 2014; 110(11):2772-84. PMC: 4037823. DOI: 10.1038/bjc.2014.175. View

19.

Verlinden L, Verstuyf A, Convents R, Marcelis S, Van Camp M, Bouillon R . Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol Cell Endocrinol. 1998; 142(1-2):57-65. DOI: 10.1016/s0303-7207(98)00117-8. View

20.

Villasenor A, Ballard-Barbash R, Ambs A, Bernstein L, Baumgartner K, Baumgartner R . Associations of serum 25-hydroxyvitamin D with overall and breast cancer-specific mortality in a multiethnic cohort of breast cancer survivors. Cancer Causes Control. 2013; 24(4):759-67. PMC: 3731052. DOI: 10.1007/s10552-013-0158-4. View